Track Bio-Rad Laboratories, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Bio-Rad Laboratories, Inc. BIO · Stock Open Bio-Rad Laboratories, Inc. in new tab

366.36 USD
P/E
9.73
EPS
37.64
P/B
1.30
ROE
14.27
Beta
1.06
Target Price
356.67 USD
Bio-Rad Laboratories, Inc. logo

Bio-Rad Laboratories, Inc.

🧾 Earnings Recap – Q3 2025

Bio-Rad's Q3 2025 results showcase stable revenue amidst macro challenges, highlighted by strong performance in process chromatography and disciplined cost management that yielded improved operating margins.

  • Q3 revenue was approximately $653 million, reflecting a 0.5% year-over-year increase but a 1.7% decline on a currency-neutral basis due to soft demand in Life Sciences and Clinical Diagnostics segments.
  • The Clinical Diagnostics segment saw a slight rise to $391 million, impacted by lower diabetes testing reimbursement rates in China, while the Life Science segment remained flat at $262 million.
  • Gross margin decreased to 52.6% from 54.8% year-over-year, primarily driven by higher material costs; however, operating income increased to approximately $65 million due to improved margin management.
  • Bio-Rad advanced its Droplet Digital PCR strategy and secured partnerships with Gencurix and Biodesix to expand its diagnostic testing capabilities, signaling potential growth avenues in the oncology space.
  • Ongoing budgetary constraints in academic research and biotech funding persist, extending the sales cycles for new products, though customer interest in new QX platforms is promising.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 11, 2027
P/E9.73
EPS37.64
Book Value282.74
Price to Book1.30
Debt/Equity17.93
% Insiders16.850%
Growth
Revenue Growth0.01%
Earnings Growth0.19%
Estimates
Forward P/E36.98
Forward EPS9.91
Target Mean Price356.67

DCF valuation

Model fair value for Bio-Rad Laboratories, Inc. (BIO)
Result
Sign in to run the valuation for BIO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Hold · mean target 356.67 USD (low 280.00, high 440.00) · as of 15 Nov 2026
Low 280.00
Mean 356.67
High 440.00
Price 366.36
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Bio-Rad Laboratories, Inc. Logo Bio-Rad Laboratories, Inc. Analysis (BIO)

United States Health Care Official Website Stock

Is Bio-Rad Laboratories, Inc. a good investment? Bio-Rad Laboratories, Inc. (BIO) is currently trading at 366.36 USD. Market analysts have a consensus price target of 356.67 USD. This suggests the asset is currently trading above analyst expectations.

In terms of valuation, the stock trades at a P/E ratio of 9.73. This relatively low multiple may signal that Bio-Rad Laboratories, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Bio-Rad Laboratories, Inc. is expected to release its next earnings report on Feb. 11, 2027. The market consensus estimate for Forward EPS is 9.91.

Investor FAQ

Does Bio-Rad Laboratories, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Bio-Rad Laboratories, Inc.?

Bio-Rad Laboratories, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 11, 2027. The company currently has a trailing EPS of 37.64.

Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Exchange Ticker
NYQ (United States) BIO
GER (Germany) BUWA.DE
FRA (Germany) BUWA.F
MCE (Spain) BIO.MC
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
March 18, 1980 2:1
Aug. 1, 1985 1.5
June 11, 1986 1.5
June 3, 1996 1.5
March 8, 2002 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion